Approxima is a spin off operating in the field of medical devices. The mission of Approxima is to develop the first minimally invasive pathology-specific therapy for the tricuspid valve. The therapy could be offered to wide spectrum of patients including those with high surgical risks. The device of Approxima directly counteracts the cause of the pathology which could favour more effective and durable clinical outcomes contributing to prolonged life expectancy and reduction of the reoperation rate.